Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma 
Background
Mometasone furoate/formoterol (MF/F) combination therapy is a new treatment for persistent asthma. We report findings from a non-inferiority study that compared effects of MF/F and fluticasone propionate/salmeterol (FP/S) combination therapies on pulmonary function and onset of action in subjects with persistent asthma.
Materials and methods
This randomized, active-controlled, multicenter, noninferiority trial enrolled subjects (≥12 yrs) previously treated with medium-dose inhaled corticosteroid alone or combined with a long-acting β 2 -agonist. 
Conclusions
This non-inferiority trial demonstrated that MDI-administered MF/F 200/10 μg BID was non-inferior to DPIadministered FP/S 250/50 μg BID in FEV 1 AUC 0-12 h . MF/ F-MDI was superior to FP/S-DPI in onset of action.
